Reuters logo
BRIEF-Xenetic Biosciences receives update from Shire's Phase 1/2 study evaluating SHP656 in development as long-acting treatment for Hemophilia A
May 22, 2017 / 11:20 AM / 4 months ago

BRIEF-Xenetic Biosciences receives update from Shire's Phase 1/2 study evaluating SHP656 in development as long-acting treatment for Hemophilia A

May 22 (Reuters) - Xenetic Biosciences Inc

* Xenetic Biosciences - receives program update from partner Shire’s phase 1/2 study evaluating SHP656 in development as a long-acting treatment for Hemophilia A

* Xenetic Biosciences Inc says additionally, there were no drug-related adverse events, serious adverse events, or RFVIII inhibitors reported

* Xenetic Biosciences Inc - “not achieving principal objective of once-weekly dosing in this Phase 1/2 study” Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below